within
nation
intern
innov
system
pandem
call
largescal
action
mani
actor
across
sector
order
mobilis
resourc
develop
manufactur
crisiscrit
product
effici
huge
quantiti
need
nowaday
also
includ
digit
innov
rang
complex
epidemiolog
model
artifici
intellig
ai
methodolog
open
data
platform
prevent
diagnost
treatment
amongst
mani
challeng
pandem
innov
stakehold
manufactur
firm
particularli
find
suddenli
engag
new
relationship
possibl
even
firm
competitor
prior
pandem
stakehold
thu
like
face
intellectu
properti
ip
relat
challeng
unfortun
government
decis
maker
challeng
might
appear
paramount
urgenc
compar
mani
huge
oper
challeng
deploy
urgent
need
resourc
howev
ip
challeng
consid
late
may
caus
delay
urgent
mobilis
resourc
effect
manufactur
firm
could
reluct
fulli
engag
develop
mass
manufactur
crisiscrit
product
purpos
provid
structur
concern
steer
clear
ip
challeng
avoid
delay
fight
pandem
adhoc
patent
analysi
identifi
major
coronaviru
relat
patent
field
around
organ
chemistri
develop
methodolog
drug
prevent
diagnosi
treatment
virus
also
identifi
timelag
outbreak
materialis
patent
applic
consist
process
patent
offic
larg
number
refer
nonpat
literatur
publish
outbreak
also
indic
urgenc
scientist
put
inform
public
domain
make
access
quickli
wider
audienc
fatal
rate
unconfirm
like
around
accord
centr
system
scienc
engin
csse
john
hopkin
univers
medicin
april
confirm
case
worldwid
death
recov
case
fig
current
countri
affect
countri
seen
exponenti
growth
rate
number
case
itali
spain
unit
state
franc
mainland
china
affect
countri
term
number
death
april
viru
stronger
transmiss
capac
convent
annual
recur
flu
averag
one
infect
person
pass
viru
other
rang
subject
chang
vari
larg
geographi
age
group
time
urgenc
respond
global
threat
pandem
unleash
plethora
effort
worldwid
tackl
pandem
quickli
possibl
health
care
remain
utmost
prioriti
among
activ
research
technolog
innov
effort
pour
support
health
care
system
develop
ramp
manufactur
crisiscrit
product
ccproduct
person
protect
equip
ppe
diagnost
test
treatment
ventil
vaccin
etc
call
exist
manufactur
incumb
oper
crisiscrit
sector
ccsector
quickli
ramp
product
capac
also
draw
variou
organis
ccsector
produc
ccproduct
prior
pandem
new
entrant
includ
larg
manufactur
firm
relat
noncrisiscrit
sector
ccsector
also
voluntari
initi
notforprofit
organis
scientist
engin
univers
research
institut
startup
form
grassroot
initi
etc
within
ccsector
open
innov
effort
involv
incumb
new
entrant
becom
essenti
address
crisiscrit
challeng
incumb
typic
crisiscrit
background
ip
ccip
relev
manufactur
ccproduct
new
entrant
lack
hand
engag
open
innov
develop
manufactur
ccproduct
new
entrant
like
develop
potenti
valuabl
foreground
ccip
pandem
purpos
first
paper
twofold
first
hope
contribut
rais
awar
ip
consider
need
address
earli
rather
later
pandem
second
provid
structur
conceptu
framework
concern
steer
clear
ip
challeng
eg
polici
maker
govern
intern
organis
larg
ip
owner
new
entrant
also
mani
voluntari
initi
part
grassroot
movement
paper
contribut
mani
effort
contain
pandem
quickli
possibl
explor
relev
ip
consider
provid
relev
terminolog
describ
patent
landscap
coronavirus
systemat
conceptualis
three
scenario
differ
ip
consider
provid
initi
discuss
possibl
approach
reduc
ip
associ
risk
relev
stakehold
thu
ensur
ip
consider
delay
fight
pandem
appli
ip
innov
perspect
enfold
pandem
provid
systemat
compil
descript
analysi
ip
issu
relev
relat
three
critic
area
fight
pandem
prevent
spread
includ
vaccin
develop
ii
develop
diagnost
ie
test
kit
determin
whether
person
infect
iii
develop
treatment
ie
preventativediagnostictreat
framework
appli
innov
ip
perspect
particularli
focu
five
technolog
relat
challeng
emerg
observ
recent
week
pandem
relat
novel
technolog
highlight
coordin
global
research
roadmap
emerg
oper
need
frontlin
healthcar
first
foremost
challeng
find
treatment
acut
respiratori
pneumonia
caus
initi
largescal
r
effort
second
pandem
creat
sudden
massiv
demand
develop
manufactur
extrem
larg
volum
diagnost
test
kit
high
accuraci
conduct
high
capac
eg
sever
week
germani
alon
carri
test
per
week
also
new
way
organis
test
done
eg
isol
pod
drive
test
third
pandem
caus
sudden
need
treat
larg
number
patient
hospit
requir
extraordinarili
larg
icu
capac
particularli
enorm
need
certain
medic
devic
particularli
ventil
capac
eg
uk
ventil
challeng
far
exceed
current
avail
capac
mani
hospit
countri
fourth
pandem
call
need
digit
innov
includ
epidem
model
monitor
understand
spread
develop
viru
across
popul
includ
track
case
spreader
fifth
pandem
caus
except
high
demand
skill
medic
staff
doctor
nurs
particularli
icu
experi
anaesthetist
critic
care
nurs
need
equip
ppe
person
protect
equip
pandem
particularli
protect
cloth
face
shield
goggl
glove
protect
health
care
staff
infect
addit
challeng
address
paper
includ
secur
suppli
chain
essenti
good
impact
drastic
reduc
passeng
cargo
transport
rout
innov
health
system
infrastructur
level
cope
test
treat
huge
number
peopl
also
secur
food
suppli
chain
supermarket
chain
play
major
role
includ
optimis
deliveri
rout
plan
quick
adjust
onlin
book
system
eg
ration
certain
good
prioritis
deliveri
slot
elderli
vulner
challeng
relat
inform
technolog
infrastructur
connect
peopl
suddenli
tri
work
home
ie
video
conferenc
platform
equip
eg
googl
microsoft
announc
free
access
advanc
teleconferenc
collabor
tool
well
internet
servic
provid
reliev
data
cap
urgent
logist
challeng
instanc
effici
reorganis
suppli
crisiscrit
product
ccproduct
repatri
nation
citizen
stuck
abroad
also
intern
oper
process
hospit
ward
repurpos
specif
test
pod
setup
list
obvious
exhaust
past
week
observ
number
respons
five
challeng
outlin
pharmaceut
biotechnolog
firm
univers
join
forc
develop
vaccin
treatment
also
test
whether
exist
antivir
drug
could
repurpos
eg
malaria
hiv
drug
develop
novel
specif
drug
instanc
collabor
clover
gsk
announc
recent
anoth
consortium
includ
life
big
pharmaceut
compani
novarti
bristol
myer
squibb
gsk
other
start
develop
novel
diagnost
test
bosch
recent
announc
develop
test
kit
manufactur
compani
kind
sector
start
repurpos
product
line
support
product
crisiscrit
product
involv
larg
engin
manufactur
firm
involv
uk
ventil
challeng
consortium
eg
airbu
gkn
rollroyc
siemen
smith
group
also
luxuri
brand
eg
french
lvhm
use
perfum
manufactur
facil
suddenli
make
hand
sanitis
well
sme
start
produc
sanitis
textil
manufactur
eg
zara
spain
trigema
germani
prada
itali
produc
face
mask
variou
volunt
initi
start
emerg
run
scientist
engin
develop
open
hardwar
sourc
design
ventil
ii
find
new
way
design
manufactur
ppe
eg
print
face
shield
ventil
valv
last
certainli
least
digit
innov
sprung
wide
eg
data
softwar
approach
scientist
prevent
diagnost
treatment
focus
prevent
digit
innov
scientist
focus
open
data
platform
develop
epidemiolog
model
understand
govern
respons
forecast
growth
curv
viru
analys
geospati
model
understand
distribut
spread
viru
deploy
causaleffect
model
understand
symptom
viru
limit
spread
behaviour
scienc
track
applic
diagnost
sphere
scientist
utilis
ai
specif
deep
convolut
neural
network
detect
xray
imag
also
particularli
use
diagnost
analysi
symptom
predict
develop
patient
case
high
number
effort
also
concentr
treatment
scientist
develop
ai
text
data
mine
tool
help
medic
commun
develop
answer
high
prioriti
scientif
question
potenti
treatment
effort
focus
develop
summaris
genom
specif
medic
protocol
precis
medicin
host
respons
well
model
simul
viru
propag
effici
intervent
emerg
pandem
news
expert
discuss
one
categor
crisiscrit
activ
three
categori
relat
innov
massiv
capac
build
upscal
manufactur
suppli
ccproduct
suffici
quantiti
short
period
time
first
categori
prevent
includ
digit
innov
track
viru
spread
sanitis
ppe
equip
etc
order
slow
spread
viru
also
vaccin
control
futur
outbreak
current
develop
second
categori
diagnost
predominantli
includ
need
incred
volum
test
kit
accur
also
portabl
deliv
speedi
result
recent
also
antibodi
test
third
categori
treatment
includ
develop
treatment
repurpos
exist
drug
develop
new
antivir
drug
also
ventil
icu
critic
care
hospit
around
world
three
categori
use
throughout
remaind
paper
gener
characterist
ip
intang
remain
larg
invis
day
day
oper
compani
economi
yet
vital
function
today
economi
normal
likewis
time
crisi
purpos
paper
defin
crisiscrit
ip
ccip
set
intellectu
properti
relev
research
develop
manufactur
distribut
crisiscrit
product
servic
technolog
urgent
need
quickli
end
crisi
situat
crisi
defin
situat
threaten
human
speci
approv
world
bodi
elev
risk
critic
ie
case
declar
situat
pandem
ccip
includ
formal
regist
ip
patent
design
right
trademark
ii
formal
unregist
ip
eg
copyright
design
draw
cad
file
trade
secret
manufactur
process
well
iii
inform
ip
knowhow
ccip
refer
alreadi
exist
background
ip
predominantli
own
incumb
alreadi
oper
ccsector
prior
crisi
well
novel
foreground
ccip
develop
crisi
variou
kind
actor
includ
incumb
also
new
entrant
ccsector
certain
ccsector
relat
technolog
product
servic
differ
degre
formal
inform
ip
product
hightech
other
previou
studi
show
ip
appear
particular
import
certain
sector
electron
ict
high
valu
manufactur
softwar
also
pharmaceut
biotechnolog
medic
devic
life
scienc
mani
ip
intens
sector
particular
relev
today
unfold
pandem
instanc
ventil
typic
expens
medic
devic
incumb
manufactur
compani
like
aliv
activ
ie
yet
expir
ccip
ppe
equip
eg
face
mask
fairli
low
tech
high
probabl
formal
relev
ccip
expir
ip
issu
hardli
surfac
begin
pandem
happen
quit
recent
exampl
summaris
wellcom
trust
appear
among
first
promin
organis
understood
relev
ip
pandem
earli
particular
focu
research
januari
trust
call
journal
publish
etc
allow
widespread
share
potenti
relev
research
dataset
initi
gear
toward
publish
put
relev
public
behind
paywal
pledg
seem
huge
success
wide
rang
renown
organis
sign
includ
lead
journal
natur
lancet
also
european
commiss
publish
eg
cambridg
univers
press
nation
academi
scienc
eg
academi
medic
scienc
royal
societi
foundat
eg
bill
melinda
gate
foundat
research
council
eg
uk
medic
research
council
ministri
eg
indian
depart
biotechnolog
ministri
scienc
technolog
wide
rang
organis
includ
compani
eg
benevolentai
johnson
johnson
research
paper
avail
onlin
past
week
organis
start
rais
concern
ip
might
issu
pandem
call
govern
privat
sector
respond
instanc
march
doctor
without
border
msf
publicli
announc
concern
firm
might
tri
profit
crisi
govern
costa
rica
call
organis
pool
relev
ip
govern
pass
compulsori
licens
resolut
ccip
eg
chile
canada
even
author
issuanc
compulsori
licens
eg
israel
compulsori
licens
kaletra
compulsori
licens
scheme
typic
kind
last
resort
govern
measur
also
observ
initi
approach
firm
taken
relat
ip
pandem
instanc
measur
mitig
risk
counterfeit
product
distribut
crisi
eg
ppe
mask
compani
enforc
ip
lawsuit
compani
develop
ccproduct
instanc
labrador
diagnost
llc
su
biofir
compani
develop
test
kit
infring
two
patent
later
announc
royalti
free
licens
anyon
develop
test
first
firm
alreadi
file
patent
form
exclus
eg
gilead
appli
orphan
drug
design
drop
day
later
critic
pharma
firm
file
repurpos
drug
extend
indic
eg
remdevir
recent
seen
limit
number
firm
adopt
least
select
open
ip
approach
particularli
pledg
relev
ip
fortress
abbvi
medic
devic
compani
manufactur
ventil
share
ip
includ
design
specif
file
irish
medtron
uk
base
smith
group
recent
initi
scientist
lawyer
launch
open
covid
pledg
wwwopencovidpledgeorg
call
ip
owner
assert
relev
ip
crisi
one
year
declar
pandem
one
main
ip
challeng
pandem
gener
avail
open
data
analys
progress
viru
well
differ
analysi
type
deploy
outbreak
sever
report
case
moment
close
million
worldwid
avail
dataset
potenti
help
deriv
insight
diseas
perform
adhoc
patent
analysi
coronavirus
use
open
dataset
lensorg
enhanc
understand
prevent
diagnost
treatment
measur
viru
focu
broader
spectrum
coronavirus
identifi
pattern
earlier
outbreak
could
appli
case
tabl
show
descript
statist
correl
patent
dataset
show
initi
result
coronaviru
patent
analysi
fig
show
top
cpc
classif
distribut
subgroup
level
evid
highest
number
patent
belong
primari
cpc
subgroup
classif
organ
chemistri
subclass
peptid
amino
acid
specif
virus
constitut
viral
protein
follow
subgroup
medicin
prepar
contain
antigen
antibodi
materi
immunoassay
coronaviru
measur
test
process
involv
enzym
nucleic
acid
microorgan
involv
viru
specif
hybrid
probe
follow
prepar
virus
bacteriophag
composit
medicin
viral
antigen
antibodi
composit
investig
process
measur
test
immunoassay
involv
enzym
investig
immunoglobulin
rna
virus
within
top
class
also
find
subclass
within
section
emerg
crosssect
technolog
specif
genet
molecular
screen
pathogen
indic
within
grant
patent
vaccin
relat
patent
avail
top
cpc
classif
specif
chemic
characterist
viru
prevent
diagnost
treatment
also
one
could
note
granular
patent
applic
field
sinc
cpc
subgroup
fig
show
top
ipc
classif
distribut
subgroup
level
uniqu
subgroup
referenc
within
patent
highest
primari
ipc
sub
group
prepar
medic
purpos
devic
method
special
adapt
bring
pharmaceut
product
particular
physic
administ
form
chemic
aspect
use
materi
deodoris
air
disinfect
sterilis
bandag
dress
absorb
pad
surgic
articl
soap
composit
coronaviru
highest
collect
number
subgroup
microorgan
enzym
composit
thereof
propag
preserv
maintain
microorgan
mutat
genet
engin
cultur
media
microbiolog
test
media
recombin
dnatechnolog
moreov
top
ipc
subgroup
fall
within
subclass
cover
follow
subject
matter
mixtur
composit
process
prepar
composit
treat
process
drug
biolog
composit
capabl
prevent
allevi
treat
cure
abnorm
patholog
condit
live
bodi
mean
destroy
parasit
organ
limit
effect
diseas
maintain
increas
decreas
limit
destroy
physiolog
bodi
function
diagnos
physiolog
condit
state
vivo
test
vitro
test
biolog
materi
rest
subclass
fall
within
class
virus
undifferenti
human
anim
plant
cell
protozoa
tissu
unicellular
alga
consid
microorgan
appear
evid
highest
cluster
patent
around
chemic
process
identif
composit
vaccin
develop
coronaviru
famili
fig
show
distribut
patent
applic
within
differ
jurisdict
show
distribut
grant
patent
within
differ
jurisdict
immedi
evid
grant
patent
lag
behind
patent
applic
old
grant
patent
fall
within
broad
spectrum
analysi
develop
vaccin
howev
patent
applic
includ
dataset
major
patent
applic
fill
us
follow
transit
wo
patent
cooper
treati
pct
follow
au
cn
ep
ca
ko
jp
distribut
grant
patent
follow
upward
trend
greater
rate
increas
patent
applic
significantli
lower
number
peak
around
grant
patent
rel
averag
patent
applic
distribut
grant
patent
within
differ
jurisdict
us
ep
au
cn
ko
ru
jp
also
interest
note
convers
rate
patent
applic
grant
patent
normal
circumst
consid
typic
ip
activ
normal
time
pandem
new
normal
analysi
ip
relat
consider
aris
effort
end
pandem
identifi
scenario
ip
relev
involv
four
main
stakehold
group
shown
analysi
find
pandem
rang
noncrisiscrit
product
ccproduct
manufactur
enter
crisiscrit
sector
ccsector
incumb
manufactur
develop
produc
suppli
crisiscrit
product
ccproduct
alreadi
pandem
exist
firm
insuffici
product
capac
suppli
crisiscrit
product
ccproduct
huge
quantiti
need
time
manner
lead
suppli
shortag
custom
firm
noncrisiscrit
sector
ccsector
print
automot
aerospac
home
applianc
fashion
luxuri
good
rush
ccsector
help
cope
ccproduct
suppli
shortag
tabl
provid
overview
ip
relat
consider
exampl
distinguish
prevent
includ
measur
limit
spread
vaccin
prevent
futur
outbreak
ii
diagnost
includ
profession
selftest
iii
treatment
latter
includ
direct
treatment
eg
develop
drug
also
treatment
symptom
ie
relat
medic
equip
need
keep
bodi
aliv
eg
ventil
icu
bed
follow
conceptu
scenario
built
distinct
group
stakehold
first
label
firm
incumb
alreadi
oper
ccsector
start
pandem
develop
manufactur
suppli
ccproduct
incumb
highli
like
ccip
pandem
start
second
label
organis
new
entrant
suddenli
rush
enter
ccsector
begin
pandem
order
support
scale
develop
manufactur
ccproduct
new
entrant
industri
manufactur
firm
type
also
voluntari
grassroot
initi
includ
notforprofit
commun
startup
entrepreneuri
scientist
etc
type
manufactur
firm
enter
ccsector
highli
like
ip
might
relev
ccip
contrast
voluntari
grassroot
initi
typic
formal
ip
prior
pandem
form
pandem
base
distinct
identifi
three
broad
scenario
discuss
exist
often
larg
manufactur
firm
produc
ccproduct
start
pandem
either
call
order
help
upscal
product
ccproduct
govern
eg
uk
govern
call
firm
produc
ventil
ii
voluntarili
switch
product
ccproduct
eg
usual
product
demand
pandem
eg
luxuri
compani
lvhm
start
produc
health
care
product
like
sanitis
hydroalcohol
gel
firm
becom
new
entrant
ccsector
appear
four
kind
new
entrant
suddenli
rush
help
produc
ccproduct
repurpos
product
line
first
despit
come
differ
sector
certain
special
compani
least
manufactur
capac
well
set
valuabl
resourc
capabl
somewhat
relat
readili
use
minim
chang
product
certain
ccproduct
meet
suppli
shortag
exampl
includ
compani
lvhm
produc
perfum
pandem
manufactur
process
equip
fill
bottl
alcohol
contain
liquid
pandem
chang
liquid
perfum
sanitis
second
type
manufactur
compani
possess
relev
expertis
resourc
compet
put
use
develop
manufactur
ccproduct
address
shortag
certain
ccproduct
exampl
uk
compani
dyson
long
airflow
busi
vacuum
cleaner
hair
dryer
expertis
air
purif
technolog
technolog
like
digit
motor
alreadi
optim
safeti
effici
dyson
henc
abl
develop
new
ventil
design
call
covent
day
anoth
exampl
gentl
mask
open
sourc
design
mask
epam
engin
softwar
solut
provid
platform
develop
third
type
includ
technolog
giant
possess
divers
capabl
rich
resourc
deploy
basic
manufactur
product
use
ip
incumb
ccsector
includ
automot
compani
enter
product
ventil
eg
volkswagen
also
multin
like
bosch
start
produc
diagnost
test
kit
access
critic
relev
knowledg
social
awar
copyright
waiver
offer
free
content
acceler
vaccin
develop
consortium
ip
pool
expertis
acceler
develop
wider
avail
test
kit
ip
share
wider
access
medicin
access
patent
eg
abbvi
agre
drop
enforc
kaletra
patent
worldwid
address
suppli
shortag
ventil
ventil
challeng
uk
consortium
acceler
develop
wider
avail
open
initi
ventil
ip
challeng
ip
imit
risk
counterfeit
product
patent
infring
lawsuit
attempt
delay
develop
test
exist
player
eg
lawsuit
labrador
diagnost
llc
biofir
declin
access
exist
crisiscrit
ip
may
lead
revers
engin
new
entrant
non
ccsector
eg
italian
volunt
print
reverseengin
valv
denial
ip
patent
barrier
product
provis
lowpric
treatment
monopoli
ccip
may
increas
product
cost
relat
medicin
turn
price
proactiv
measur
govern
implement
compulsori
licens
patent
eg
drug
relat
patent
includ
product
process
patent
patent
technolog
medic
equip
like
ventil
valv
new
patent
eg
isinnova
plan
patent
charlott
valv
copyright
free
copyright
open
access
articl
provid
access
relev
knowledg
research
would
otherwis
avail
ip
strategi
best
suit
help
achiev
ip
purpos
consortia
among
big
pharma
compani
acceler
develop
manufactur
deliveri
vaccin
diagnost
treatment
pledg
give
free
access
ccip
limit
time
voluntarili
thirdparti
platform
eg
open
covid
pledg
hackathon
share
gener
idea
open
platform
share
dataset
sourc
code
fourthli
see
compani
possess
set
particular
skill
agil
speedili
develop
basic
kind
complex
product
often
possess
fairli
flexibl
manufactur
facil
equip
often
limit
low
volum
product
exampl
includ
formula
one
team
william
race
mclaren
join
uk
ventil
challeng
consortium
four
type
compani
typic
formal
ip
firm
mostli
larg
commonli
oper
inhous
ip
depart
thu
possess
awar
ip
relev
understand
ip
function
howev
ip
develop
start
pandem
might
exactli
relev
ccsector
enter
ccsector
support
scale
ccproduct
manufactur
new
entrant
need
understand
quickli
start
manufactur
ccproduct
larg
volum
essenti
three
option
regard
ip
first
option
worri
care
incumb
ccip
go
ahead
thu
wil
infring
exist
ccproduct
reverseengin
incumb
ccproduct
circumst
owner
ccip
may
deni
access
proprietari
inform
knowhow
eg
italian
print
volunt
deni
access
proprietari
inform
ventil
valv
forc
reverseengin
design
case
enforc
ip
pursu
new
entrant
infring
far
rare
eg
case
labrador
diagnost
llc
previous
mention
understand
pandem
due
potenti
reput
damag
howev
new
entrant
choos
option
might
becom
futur
target
infring
claim
incumb
pandem
end
new
entrant
often
larg
firm
repurpos
larg
manufactur
unit
also
wellestablish
sme
enter
product
ccproduct
eg
local
distilleri
start
produc
sanitis
print
compani
produc
ppe
given
small
scale
might
particularli
prone
attack
incumb
ip
owner
would
vulner
posit
situat
aris
second
option
new
entrant
start
design
ccproduct
scratch
possibl
use
engin
design
compet
abil
procur
rapid
expert
advic
exampl
dyson
ventil
design
covent
develop
partnership
medtech
consult
technolog
partnership
ttp
effort
led
coalit
larg
technolog
consult
cambridg
consult
typic
work
medic
devic
project
client
without
hold
ip
howev
start
ground
might
effici
way
achiev
impact
pandem
develop
obtain
medic
approv
new
ccproduct
design
like
caus
delay
choos
option
new
entrant
would
essenti
develop
novel
ccip
howev
carri
care
freedom
oper
analysi
may
infring
exist
background
ccip
own
incumb
carri
freedom
oper
analysi
may
delay
quick
manufactur
ccproduct
new
entrant
left
balanc
risk
uncertainti
rapid
chang
technolog
regulatori
econom
legal
landscap
third
option
access
ccip
team
incumb
produc
exist
ccproduct
manufactur
prior
pandem
incumb
instanc
smith
group
penlon
incumb
ventil
design
join
uk
ventil
challeng
consortium
compani
grant
licens
share
ccip
consortium
partner
includ
new
entrant
incumb
eg
medtron
select
pledg
ccip
puritan
bennetttm
basic
ventil
model
made
avail
design
manufactur
detail
permiss
licens
limit
term
new
entrant
access
ccip
way
way
avoid
infring
exist
ip
own
incumb
incumb
pledg
ccip
way
facilit
adopt
technolog
pandem
potenti
last
benefit
beyond
pandem
instanc
share
ccip
pandem
freeli
without
charg
royalti
use
licens
time
limit
compani
want
continu
use
ip
beyond
pandem
licens
term
would
either
prevent
compani
would
pay
royalti
whether
new
entrant
start
develop
design
ccproduct
scratch
licens
exist
ccip
infring
upon
exist
ccip
scale
product
use
resourc
new
entrant
like
develop
novel
foreground
ccip
given
face
resourc
constraint
manufactur
ccproduct
equip
dispos
materi
access
quickli
exist
supplier
relationship
well
may
end
adapt
exist
design
may
lead
find
invent
design
way
eg
manufactur
ccproduct
cheaper
way
new
entrant
could
possibl
consid
formal
regist
new
ccip
eg
file
patent
suddenli
incumb
may
find
confront
new
entrant
sector
infring
ccip
extent
find
difficult
enforc
pandem
new
entrant
develop
subsequ
ccip
incumb
may
fear
new
entrant
continu
stay
sector
ie
ccsector
even
pandem
eventu
end
establish
capabl
manufactur
ccproduct
innov
way
use
innov
design
eg
low
cost
version
less
develop
countri
new
entrant
may
incent
stop
produc
ccproduct
exit
ccsector
incumb
may
find
help
establish
new
competitor
enforc
ccip
pandem
extent
concern
depend
incumb
exist
busi
model
ip
strategi
interact
strategi
new
entrant
therefor
difficult
predict
present
sever
concern
whether
justifi
past
week
observ
larg
number
newli
launch
voluntari
grassroot
initi
notforprofit
organis
startup
join
develop
product
ccproduct
initi
often
adopt
explicitli
implicitli
open
sourc
approach
wide
share
design
seem
distinguish
two
categori
initi
first
seen
number
highli
innov
voluntari
initi
got
activ
help
develop
manufactur
ccproduct
typic
found
highli
skill
peopl
engin
scientist
often
develop
fairli
complex
hightech
ccproduct
includ
hardwar
ventil
also
data
platform
collat
pandem
data
track
applic
instanc
larg
number
institut
develop
complex
epidemiolog
model
geospati
model
understand
spread
develop
viru
togeth
behaviour
scienc
well
discuss
differ
approach
use
govern
nonmed
intervent
slow
pandem
import
develop
utilis
artifici
intellig
ai
methodolog
specif
deep
convolut
neural
network
detect
xray
imag
well
identifi
develop
stage
diseas
quickli
sever
initi
come
stun
new
afford
easi
produc
ccproduct
design
often
undergon
highli
sophist
test
state
art
equip
scientist
access
lab
initi
typic
share
design
draw
cad
file
well
test
data
open
sourc
approach
either
formal
adopt
open
sourc
hardwar
softwar
licenc
inform
statement
intent
initi
develop
novel
foreground
ccip
typic
build
exist
design
adopt
outbound
licens
open
ip
approach
potenti
residu
risk
design
may
actual
infring
upon
exist
ccip
initi
usual
limit
ip
expertis
lack
resourc
access
extern
legal
support
eg
patent
attorney
unlik
initi
conduct
freedom
oper
analysi
launch
novel
ccproduct
lack
due
dilig
ip
clearanc
open
sourc
initi
probabl
exclud
liabil
warranti
design
could
lead
industri
adopt
start
produc
open
sourc
design
volum
troubl
suddenli
unwillingli
infring
incumb
ccip
second
categori
includ
variou
initi
focu
redesign
new
manufactur
approach
lowtech
ccproduct
ie
low
technic
manufactur
complex
ccproduct
includ
face
mask
seen
numer
initi
releas
pattern
onlin
call
home
product
ie
crowdmanufactur
initi
might
seen
highli
innov
industri
standpoint
produc
fairli
matur
date
ccproduct
might
protect
anymor
aliv
ip
instanc
patent
protect
face
mask
design
may
long
expir
howev
variou
initi
focus
lowtech
ccproduct
clearli
innov
develop
novel
solut
go
beyond
exist
ccproduct
instanc
differ
initi
start
develop
new
face
shield
design
optimis
print
initi
develop
potenti
patent
novel
ccip
necessarili
infring
incumb
own
ccip
probabl
alreadi
expir
overal
initi
may
run
particular
infring
risk
howev
like
creat
novel
foreground
ccip
given
initi
adopt
open
sourc
licens
approach
may
formal
seek
protect
novel
ccip
file
patent
howev
possibl
expect
see
trademark
registr
appear
initi
becom
commerci
viabl
eg
also
start
mass
print
product
face
shield
lithuania
certain
expertis
like
vaccin
drug
develop
uniqu
incumb
ccsector
new
entrant
less
almost
unlik
contribut
significantli
within
short
time
frame
avail
pandem
case
incumb
ccsector
develop
new
solut
contribut
upscal
may
end
infring
ccip
incumb
analysi
show
incumb
may
take
one
follow
three
approach
come
differ
ip
consider
one
approach
develop
new
technolog
solut
base
prepandem
technolog
expertis
uniqu
ccsector
therebi
independ
creat
innov
novel
ccip
within
expertis
exampl
covid
test
develop
biofir
claim
base
exist
technolog
eg
biofir
filmarray
second
approach
ccsector
incumb
prepandem
compon
supplier
suddenli
establish
larg
scale
manufactur
unit
address
supplyshortag
exampl
ineo
chemic
giant
supplier
one
key
ingredi
use
sanitis
establish
huge
manufactur
capac
franc
produc
million
bottl
per
month
third
approach
requir
incumb
collabor
form
bilater
collabor
eg
agreement
eli
lilli
abcellera
establish
new
consortia
eg
opencorona
consortium
therapeut
acceler
join
exist
network
eg
cepi
coalit
epidem
prepared
innov
europ
imi
innov
medicin
initi
share
ip
among
acceler
effort
consortium
like
includ
noncommerci
entiti
univers
research
centr
analysi
show
consortium
prevent
stage
focu
mainli
vaccin
develop
exampl
includ
horizon
opencorona
consortium
consortium
among
novarti
bristol
myer
squibb
gsk
consortium
involv
univers
research
centr
treatment
consortium
ccproduct
eg
uk
ventil
challeng
consortium
drug
eg
see
sever
r
effort
incumb
two
ccip
consider
identifi
three
approach
taken
incumb
first
effort
incumb
acceler
ccproduct
develop
may
conduct
freedom
oper
analysi
time
take
may
end
face
infring
lawsuit
incumb
own
similar
ccip
eg
labrador
diagnost
llc
lawsuit
biofir
second
prepandem
supplier
establish
mass
product
manufactur
unit
might
gener
foreground
ip
pandem
would
like
stay
market
post
pandem
well
summaris
fig
new
entrant
rush
help
larg
scale
product
hightech
ccproduct
eg
ventil
product
diagnost
kit
particularli
larg
one
enter
ccsector
might
risk
infring
activ
aliv
ccip
own
incumb
enter
low
tech
ccproduct
formal
relev
ip
might
alreadi
expir
eg
face
mask
free
altern
exit
overal
larg
firm
might
risk
becom
target
futur
ie
pandem
infring
claim
sme
voluntari
initi
particular
consider
mention
rush
ccproduct
manufactur
larg
firm
may
perceiv
ip
urgent
given
current
crisi
could
turn
difficult
long
run
could
come
consider
ip
risk
incumb
owner
ccip
might
lower
probabl
sue
voluntari
initi
claim
damag
could
ask
injunct
may
caus
reput
damag
except
might
case
ccproduct
develop
voluntari
initi
produc
larg
volum
howev
voluntari
initi
give
away
ip
open
sourc
would
make
suffici
money
damag
claim
target
rather
manufactur
open
sourc
design
without
clean
freedom
oper
situat
could
target
infring
claim
one
also
consid
new
entrant
whether
larg
manufactur
firm
voluntari
initi
like
develop
novel
ccip
pandem
could
use
continu
stay
ccsector
pandem
characteris
crisi
call
urgent
immin
largescal
action
govern
industri
player
well
rang
societ
actor
govern
take
centr
stage
orchestr
rapid
respons
pandem
one
mani
primari
concern
enabl
larg
scale
product
crisiscrit
product
ccproduct
demand
typic
far
exceed
manufactur
capac
avail
incumb
manufactur
crisiscrit
sector
ccsector
call
firm
enter
ccsector
support
mass
manufactur
ccproduct
repurpos
manufactur
line
lead
situat
manufactur
firm
find
suddenli
engag
new
relationship
eg
uk
ventil
challeng
possibl
even
compani
competitor
pandem
pandem
exemplifi
current
crisi
also
lead
wide
rang
innov
activ
whether
incumb
new
entrant
larg
firm
variou
grassroot
initi
notforprofit
organis
startup
etc
govern
prioriti
must
enabl
mass
product
ccproduct
forget
address
potenti
ip
concern
incumb
new
entrant
may
think
way
reduc
ip
relat
risk
least
three
possibl
approach
avail
support
reduct
ip
associ
risk
one
legal
approach
govern
stem
trip
agreement
compulsori
licens
tool
govern
countri
adopt
trip
allow
govern
use
ip
crisi
situat
pandem
howev
compulsori
licens
typic
seen
last
resort
measur
compulsori
licens
particularli
help
govern
access
use
ccip
therebi
reduc
ip
associ
risk
mostli
new
entrant
usual
favour
incumb
even
though
govern
typic
agre
pay
reason
royalti
access
ip
current
pandem
countri
alreadi
consid
compulsori
licens
expect
includ
chile
canada
israel
anoth
voluntari
approach
call
owner
ccip
mostli
incumb
pledg
ip
new
entrant
get
nonexclus
licens
use
incumb
ccip
least
durat
pandem
exampl
includ
firm
specif
pledg
eg
medtron
abbvi
smith
also
open
covid
pledg
wwwopencovidpledgeorg
industri
relev
ip
well
wellcom
trust
pledg
research
public
dataset
pledg
option
particularli
time
limit
licens
appear
friendli
incumb
also
derisk
ip
challeng
new
entrant
pledg
often
also
provid
licens
templat
other
use
adjust
need
anoth
approach
reduc
ip
associ
risk
thu
avoid
delay
fight
pandem
ccip
pool
made
avail
restrict
group
compani
eg
consortium
interest
firm
want
use
ip
formal
approach
govern
would
facilit
develop
patent
pool
alreadi
use
pharmaceut
industri
eg
medicin
patent
pool
coronaviru
viru
famili
belong
viru
caus
paper
show
research
ip
protect
coronaviru
relat
invent
new
patent
protect
differ
form
coronaviru
alreadi
exist
particular
coronaviru
type
caus
diseas
also
evid
timelag
outbreak
materialis
patent
high
number
citat
nonpat
literatur
show
urgenc
scientist
open
data
put
inform
public
domain
make
difficult
ip
given
requir
consider
earli
stage
pandem
enorm
sens
urgenc
easili
draw
decis
maker
attent
huge
undoubtedli
urgent
oper
challeng
paper
hope
contribut
rais
awar
ip
need
dealt
rather
earlier
later
pandem
order
avoid
ip
associ
risk
delay
mobilis
resourc
urgent
need
research
develop
mass
manufactur
crisiscrit
product
paper
provid
terminolog
help
conceptualis
ip
consider
time
pandem
global
crisi
call
urgent
largescal
action
industri
stakehold
suddenli
find
engag
new
relationship
associ
variou
uncertainti
least
relat
use
share
ip
particular
problem
negoti
licens
agreement
typic
time
consum
analys
current
unfold
pandem
identifi
ip
associ
challeng
relat
prevent
diagnosi
treatment
pandem
identifi
four
type
stakehold
mostli
concern
ip
consider
includ
govern
intergovernment
organis
wipo
call
upon
orchestr
pandem
respons
incumb
manufactur
firm
ccsector
well
new
entrant
enter
crisiscrit
sector
assist
incumb
new
entrant
manufactur
firm
produc
crisiscrit
product
prior
pandem
also
voluntari
grassroot
initi
startup
entrepreneuri
scientist
etc
identifi
analys
three
scenario
differ
consider
around
ip
emerg
first
scenario
manufactur
firm
enter
crisiscrit
sector
assist
incumb
mass
manufactur
volum
requir
crisiscrit
product
firm
possess
complementari
capabl
resourc
repurpos
product
line
second
scenario
discuss
ip
consider
voluntari
grassroot
initi
enter
crisiscrit
sector
third
scenario
discuss
r
manufactur
engag
ip
consider
incumb
ccsector
final
provid
initi
discuss
three
possibl
approach
address
ip
concern
pandem
name
compulsori
licens
ip
pledg
ip
pool
